Gil Roth07.27.11
Hospira 2Q
2Q Revenues: $1.1 billion (+10%)
2Q Earnings: $144 million (+72%)
YTD Revenues: $2.1 billion (+5%)
YTD Earnings: $294 million (+30%)
Comments: Revenue growth in 2Q11 was driven primarily by sales of oncolytic docetaxel in the Specialty Injectables group. Sales for that unit were $675 million (+18%) in 2Q and $1.3 billion YTD (+11%). Sales for Other Pharma, which includes contract manufacturing, were down 5% for 2Q ($142 million) and down 10% YTD ($266 million).
2Q Revenues: $1.1 billion (+10%)
2Q Earnings: $144 million (+72%)
YTD Revenues: $2.1 billion (+5%)
YTD Earnings: $294 million (+30%)
Comments: Revenue growth in 2Q11 was driven primarily by sales of oncolytic docetaxel in the Specialty Injectables group. Sales for that unit were $675 million (+18%) in 2Q and $1.3 billion YTD (+11%). Sales for Other Pharma, which includes contract manufacturing, were down 5% for 2Q ($142 million) and down 10% YTD ($266 million).